Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion
Copyright 2013, SLACK Incorporated.
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 44(2013), 4 vom: 12. Juli, Seite 334-43 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2013
|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina |
| Sujets: | Journal Article Fibrinolytic Agents Peptide Fragments microplasmin 7V6HE3DM5A Fibrinolysin EC 3.4.21.7 |
| Résumé: | Copyright 2013, SLACK Incorporated. BACKGROUND AND OBJECTIVE: When delivered via a single intravitreal injection, ocriplasmin can effect proteolytic resolution of symptomatic vitreomacular adhesion (VMA). The authors describe their initial clinical experience with ocriplasmin at a large academic center PATIENTS AND METHODS: Retrospective review of all patients with symptomatic VMA treated with ocriplasmin from January 2013 through May 2013 at a single center RESULTS: Nineteen patients with symptomatic VMA received intravitreal ocriplasmin. Eight patients (42%) exhibited resolution of VMA. Macular holes in three of six patients (50%) closed after injection. A higher proportion of VMA resolution was observed in patients with the following baseline characteristics: age less than 65 years, focal adhesions less than or equal to 1,500 μm, presence of macular hole, phakic status, and absence of epiretinal membrane CONCLUSION: Initial clinical outcomes using ocriplasmin in this study are consistent with those reported in the phase 3 clinical trials. Improved clinical results can be achieved with careful case selection based on specific baseline characteristics |
|---|---|
| Description: | Date Completed 06.02.2014 Date Revised 25.11.2016 published: Print CommentIn: Ophthalmic Surg Lasers Imaging Retina. 2013 Jul-Aug;44(4):319. doi: 10.3928/23258160-20130715-01. - PMID 23883265 Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20130715-05 |